Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral hepatitis C.

Thierry Poynard1, Man-Fung Yuen, Vlad Ratziu

  • 1Service d'Hépato-gastro-entérologie, Groupe Hospitalier Pitié-Salpêtriére, Université, Paris, France. tpoynard@teaser.fr

Lancet (London, England)
|December 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations between gut microbiome and 24-hour blood pressure variability: a cross-sectional study highlighting sex differences and potential therapeutic targets.

Gut microbiome (Cambridge, England)·2026
Same author

Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosis.

The American journal of gastroenterology·2026
Same author

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

The New England journal of medicine·2026
Same author

The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial.

The lancet. Gastroenterology & hepatology·2026
Same author

GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes.

Hepatology (Baltimore, Md.)·2026
Same author

Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort.

Journal of hepatology·2026

Chronic hepatitis C virus (HCV) infection affects over 170 million globally, leading to liver cancer and other severe complications. Antiviral treatments show promise in eradicating the virus and reversing liver damage, but detection and treatment gaps persist.

Area of Science:

  • Hepatology
  • Virology
  • Molecular Biology

Background:

  • Hepatitis C virus (HCV) chronically infects over 170 million people worldwide.
  • HCV is a leading cause of liver cancer, digestive hemorrhage, and ascites.
  • Significant advancements in diagnosis and treatment have been achieved.

Purpose of the Study:

  • To assess the replicative state of the hepatitis C virus.
  • To evaluate the efficacy of antiviral treatments for HCV.
  • To highlight the impact of detection and treatment on patient outcomes.

Main Methods:

  • Utilizing advances in molecular biology to assess viral replicative state.
  • Employing genotype and serum viral load as predictors of treatment response.
  • Administering combination therapy with pegylated interferon and ribavirin.

Related Experiment Videos

Main Results:

  • Pegylated interferon and ribavirin eradicated the virus in over 50% of patients.
  • Antiviral treatments demonstrated efficacy in reducing liver fibrosis progression.
  • These therapies showed potential in reversing cirrhosis.
  • Despite treatment advances, mortality from hepatitis C is increasing due to inadequate detection and treatment.

Conclusions:

  • Hepatitis C virus (HCV) remains a significant global health burden.
  • Current antiviral therapies offer effective viral eradication and disease modification.
  • Improved detection and treatment strategies are crucial to reduce hepatitis C-related mortality.